Ongoing strategic partnership advances joint pipeline in neurodegeneration research Evotec receives a $20 million payment to ...

EQS-AFR: Evotec SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements ...

The collaboration has already yielded strong results, including the in-licensing of EVT8683 (now BMS-986419) by Bristol Myers Squibb in September 2021. In March 2023, the companies reaffirmed their ...

Triggers a $20 million research payment to Evotec, enabling further development of a preclinical program in neurodegeneration ...

HAMBURG, DE / ACCESS Newswire / March 4, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN:DE0005664809; NASDAQ:EVO) today announced another major accomplishment in its long ...

Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the ...

Ongoing strategic partnership advances joint pipeline in neurodegeneration researchEvotec receives a $20 million payment to further progress research HAMBURG, DE / ACCESS Newswire / March 4, 2025 / Ev ...

This page uses Cookies. For proper functioning of the page Cookies are needed. You agree to using Cookies by clicking "OK". More infos can be found in our Privacy declaration . If you disagree this ...

US biotech Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been "unwilling to engage with us to explore a potential combination." Halozyme made ...

The microbial fermentation technology market is experiencing significant growth, fueled by the increasing incidence of chronic diseases like cancer a ...